Silverback Therapeutics SBTX

$ 6.1 4.99%

Quarterly report 2024-Q3
added 11-13-2024

Silverback Therapeutics Balance Sheet 2011-2024 | SBTX

Annual Balance Sheet Silverback Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-70.7 M	-210 M	-59.4 M	-383 M	5.64 M	-12.4 M	-	-	-	-	-	-	-
Long Term Debt	37 K	251 K	480 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	237 K	230 K	144 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	2.33 M	56.5 M	57.4 M	-	-	-	-	-	-	-
Total Current Liabilities	2.39 M	5.44 M	8.19 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	2.43 M	8.55 M	16.7 M	11.9 M	74.4 M	62.5 M	-	-	-	-	-	-	-
Deferred Revenue	-	283 K	1.46 M	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-131 M	-76.9 M	-42.3 M	-96.7 M	-63.8 M	-39.8 M	-	-	-	-	-	-	-
Total Assets	233 M	281 M	61.4 M	395 M	15.6 M	27.5 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	71 M	211 M	60.1 M	387 M	-	-	-	-	-	-	-	-	-
Book Value	231 M	273 M	44.8 M	383 M	-58.8 M	-35 M	-	-	-	-	-	-	-
Total Shareholders Equity	231 M	273 M	-31.3 M	383 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Silverback Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	37 K	92 K	146 K	199 K	251 K	-	4.06 M	4.43 M	4.76 M	5.08 M	1.78 M	2.06 M	2.33 M	2.33 M	2.33 M	2.33 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	16.6 M	6.72 M	3.72 M	2.43 M	11.3 M	10.2 M	10 M	8.55 M	3.99 M	15.2 M	19.2 M	19.7 M	20.4 M	17.3 M	13.6 M	11.9 M	11.9 M	11.9 M	11.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	10 K	283 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-173 M	-154 M	-142 M	-131 M	-124 M	-109 M	-91.9 M	-76.9 M	-248 M	-230 M	-211 M	-186 M	-163 M	-140 M	-116 M	-96.7 M	-96.7 M	-96.7 M	-96.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	218 M	222 M	228 M	233 M	249 M	259 M	271 M	281 M	271 M	294 M	312 M	333 M	353 M	367 M	382 M	395 M	395 M	395 M	395 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	39.7 M	36.6 M	56 M	71 M	60.5 M	119 M	87.9 M	211 M	37.3 M	44.6 M	52.2 M	254 M	301 M	360 M	374 M	387 M	387 M	387 M	387 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	201 M	215 M	224 M	231 M	237 M	249 M	261 M	273 M	267 M	279 M	293 M	314 M	332 M	350 M	369 M	383 M	383 M	383 M	383 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	201 M	215 M	224 M	231 M	237 M	249 M	261 M	273 M	-50.2 M	-44 M	-38.3 M	314 M	332 M	350 M	369 M	383 M	383 M	383 M	383 M	-58.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency